Reduced intensity, or non-myeloblative stem cell transplantation (NST) is designed to induce host-versus-graft tolerance by engraftment of donor stem cells. The rationale behind NST is to induce optimal graft-versus-leukemia (GVL) effects for elimination of all malignant cells by donor alloreactive immunocompetent cells as an alternative to standard high-dose myeloablative chemoradiotherapy. NST based on the use of fludarabine, low-dose busulfan and anti-T-lymphocyte globulin (ATG), was employed in 24 patients with chronic myeloid leukemia (CML) in first chronic phase (CP) aged 3-63 years. Graft-versus-host disease (GVHD) prophylaxis consisted of low-dose cyclosporine (CSP), some with low-dose methotrexate. Early discontinuation of CSP was attempted in cases of mixed chimerism in an attempt to amplify GVL effects. All 24 patients showed rapid 3-lineage engraftment, mostly without complete aplasia; 6 patients did not require transfusion of any blood products. NST was associated with minimal procedure-related toxicity. The incidence of acute GVHD grade I was 54%, however, this increased following CSP withdrawal. After a follow-up of up to 70 (median 42) months 21/24 patients remain alive and free of disease. The GVL effects induced by donor immunocompetent lymphocytes eradicated all host hematopoietic cells, as evidenced by molecular testing. The Kaplan-Meier probability of survival and disease-free survival at 5 years is 85±8% (confidence interval 70-100%). NST may successfully replace myeloablative stem cell transplantation, thus providing a safer, well tolerated therapeutic option for all patients with CML in first CP with a matched donor, however, this conclusion must be tested in a prospective randomized clinical trial.
Introduction
The use of bone marrow transplantation (BMT) for chronic myeloid leukemia (CML) from a fully matched donor is considered a most effective curative modality (1, 2) . Until recently, myeloablative conditioning was considered mandatory for the elimination of malignant hematopoietic cells and for prevention of allograft rejection.
However, animal experiments in the 1960's (3, 4) , and clinical observations in the 1970' confirmed that immune-mediated graft-versus-leukemia (GVL) effects play the most important role in the course of BMT (5, 7) . Furthermore, since 1987 we have documented that donor lymphocyte infusion (DLI) post-grafting, with no additional chemotherapy, can eliminate leukemia cells even in patients fully resistant to maximally tolerated doses of chemoradiotherapy (8, 9) . Since then, DLI has been confirmed as the most effective therapeutic modality, especially for patients with CML with residual or recurrent disease following BMT (10) (11) (12) . The rate of complete remission in response to DLI has been impressive, with 70-80% of relapsed CML patients accomplishing durable remissions following DLI (8) (9) (10) (11) (12) , with lower success rates in other diseases treated by BMT (13) (14) (15) (16) (17) (18) (19) (20) (21) . Given the unequivocal therapeutic role of donor lymphocytes in patients with CML (22) and considering the documented therapeutic potential of alloreactive donor lymphocytes administered post-BMT in CML patients relapsing following maximally tolerated doses of chemoradiotherapy (8) (9) (10) (11) (12) , it seemed reasonable to exploit the therapeutic use of alloreactive donor lymphocytes following establishment of host-to-graft transplantation tolerance induced by engraftment of donor stem cells following reduced intensity, lymphoablative yet non-myeloablative, conditioning (23).
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From 4 The present report summarizes our cumulative experience in a cohort of (24) consecutive patients with CML in first chronic phase and confirms that durable remission, with eradication of molecular evidence of disease, can be accomplished without myeloablative conditioning, thus avoiding or minimizing procedure-related toxicity and mortality.
Patients and Methods
Twenty-four consecutive patients with Philadelphia positive CML, in first chronic phase were enrolled in this study, according to previously published criteria (24) .
Patients were included if they were proved to be in stable first chronic phase and The details of the mobilized incoculum are presented in Table 2 . Prior to NST, all patients received trimethoprim/sulfamethoxazole (10 mg/kg/day trimethoprin) on days -10 to -2, acyclovir (500 mg/m 2 x 3/day) from days -6 until day +100, and allopurinol (300 mg/day) on days -10 to -1. Administration of trimethopri m/sulfamethoxazole (twice weekly) was reinstituted after recovery from neutropenia as a preventive measure against pneumocystis carinii infection. CMV infections (diagnosed by 2 successive positive PCR's) were treated with ganciclovir 10 mg/kg/day.
Graft-vs-host disease prophylaxis consisted of single-drug low-dose, short-term CSP 3 mg/kg i.v. daily in two divided doses starting on day -1 in the first 19 patients.
The remaining 5 patients received methotrexate in addition: 15mg/m 2 on day +1 and 10 mg/m 2 on days +3 and +6. Once the patients were dehospitalized, CSP was administered orally. CSP dosage was tapered during the second or third month post transplant, according to chimeric status and evidence of GVHD.
Neutropenic patients with culture-negative fever received a combination of gentamicin, cefazolin and mezlocillin, as a first line antibiotic protocol. Persisting fever was treated with amikacin and tazocin as a second line protocol, while imipenem was used as the third line protocol. In cases of persistent fever not responding to antibiotic therapy within 5 days, amphotericin B (1 mg/kg every other day) was added until the neutropenia resolved. Starting on day -10, a DNA-PCR test was done weekly to detect cytomegalovirus (CMV). Two consecutive positive PCR results served as an indication for replacing acyclovir with ganciclovir until a minimum of two negative tests was obtained.
Patients were treated in reverse isolation rooms equipped with HEPA filters, and received a regular diet. Additional supportive measures, such as parenteral nutrition and blood component transfusion were administered as necessary.
Acute and chronic GVHD were graded according to the Glucksberg's criteria (25) . Immediately upon the appearance of signs and symptoms of GVHD, i.v. methyprednisolone (2 mg/kg) and CSP were administered.
In order to assess engraftment, degree of chimerism, minimal residual disease and early relapse, patients were monitored at regular interval by cytogenetic analysis, and by donor and host-specific DNA markers, including male and female amelogenine gene PCR bands (26) , and by VNTR-PCR assay (27) . Cytogenetic analysis for Philadelphia chromosome and the BCR/ABL RT-PCR test were applied at the time of diagnosis and for detection of relapse during follow-up (28) .
Results
The protocol used for conditioning was well tolerated by all 24 patients. Patients were free to leave the hospital in between treatment schedules and 9 were treated partially on an outpatient basis. The large majority of patients did not experience oral mucositis, thus being maintained on normal oral intake; 34% of the entire group required supplemental parenteral nutrition. Moderate to severe hepatic veno-occlusive disease (VOD) occurred in 3 patients, but resolved completely within 3 months. Fever Mortality at day +100 was zero, indicating that NST was well tolerated by all patients in all age groups. Within an observation period of 7 -63 (median 37) months following NST, both the overall survival and disease-free survival ( Fig. 1) were Acute GVHD ( grade I) occurred in 13/24 patients (probability 54% with 95% confidence interval of 34-74%) while on CSP (1 grade I, 7 grade II, 2 grade III and 3 grade IV). Early withdrawal of CSP, in 7 patients, in order to facilitate engraftment and eliminate residual host cells, resulted in 6 additional cases of acute GVHD (1 grade I, 3 grade II and 2 grade IV; thus accounting for an overall cumulative probability of acute GVHD of 75% (95%, confidence interval of 58-92%) (Fig. 2) .
The overall incidence of severe acute GVHD (grade III-IV), including 2 patients that developed grade IV GVHD only when CSP was discontinued was 29% (95% confidence interval of 2-47%) (Fig. 2) . In 11 patients acute GVHD progressed to chronic GVHD. Four of these, developed acute GVHD while on CSP, and one, developed acute GVHD following early discontinuation of CSP. Only one patient developed de novo mild chronic GVHD ( Table 1 ). The overall probability of chronic GVHD was 55% (95% confidence interval of 44-75%) (Fig. 3) . Three patients died as a consequence of GVHD, one on day +116 due to acute GVHD, another on day +499 due to chronic GVHD and invasive fungal infection and the third patient on day +726 due to chronic GVHD and recurrent infections (Table 3) . These were the only fatalities recorded in this series. (95% confidence interval 70-100%) (Fig. 1 ).
Discussion
Our data based on a cohort of 24 patients with CML in first chronic phase suggest that Allogeneic stem cell transplantation is the only proven cure for CML, however, the standard myeloablative procedure is associated with early toxicity and mortality and late complications (1,2,37-39). Therefore, there is a dilemma in using BMT for patients with asymptomatic CML that can be well controlled, though not necessarily cured, with conventional cytoreductive agents like hydroxyurea, interferon or the tyrosine kinase inhibitor STI571 (Glivec) (40). Delaying transplantation in CML involves a complex decision, as best results are achieved if patients are transplanted while still in chronic phase, and preferably within the first year of diagnosis.
Whereas postponement of BMT may be justified in patients responding to alpha interferon or Glivec, other patients showing resistance to these agents, or in patients with advanced stages of disease, BMT should be offered immediately. Due to anticipated procedure-related toxicity, BMT is seldom offered to elderly patients, even when the indication is unequivocal, due to increased procedure-related mortality (24) . Results from younger patients who underwent BMT following a conventional myeloablative preparatory regimen, with high dose cytoxan and busulfan or TBI, which were considered mandatory until recently, are unsatisfactory in many centers due to acceptable procedure related toxicity and mortality in young patients (37-39). However, using more intensive cytoreductive reigmen, including higher dose TBI or additional splenic irradiation as part of the conditioning, confers no significant benefit over conventional protocols (38, 39, 41, 42) .
The efficacy of well-tolerated NST in CML as suggested by our data could be predicted by the efficacy of elimination of molecular evidence of disease in the large majority of CML patients who relapse following myeloablative BMT following treatment with DLI alone (8) (9) (10) (11) (12) . Occasionally, as shown herewith and as reported earlier in recipients of conventional BMT, discontinuation of CSP alone can result in regression or relapse (43). Likewise, there seems to be an increased risk of leukemia relapse in patients Elimination of all measurable evidence of disease and documentation of durable remission in our small cohort of patients, despite the use of a reduced intensity conditioning, is most encouraging. Based on the data presented and considering the 
